
Wednesday, March 14, 2018 11:39:53 PM
LB-294 / 16 - Synergy of an anti-HER2 ADC TAK-522 (XMT-1522) in combination with anti-PD1 monoclonal antibody (mAb) in a syngeneic breast cancer model expressing human HER2
http://www.abstractsonline.com/pp8/#!/4562/presentation/10611
Also poster on differentiation of ADC platform...
754 / 21 - Unique pharmacologic properties of Dolaflexin-based ADCs—a controlled bystander effect
http://www.abstractsonline.com/pp8/#!/4562/presentation/3082

Liked By
Spread the love. Be the first to like this post!
Recent MRSN News
- Current Report Filing (8-k) • Edgar (US Regulatory) • 01/25/2023 01:25:17 PM
- Mersana Therapeutics Announces Initiation of Phase 1 Trial of XMT-2056 in HER2-Expressing Tumors • GlobeNewswire Inc. • 01/25/2023 01:00:00 PM
- Amended Statement of Ownership (sc 13g/a) • Edgar (US Regulatory) • 01/19/2023 09:07:23 PM
- Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 01/06/2023 09:05:00 PM
- Current Report Filing (8-k) • Edgar (US Regulatory) • 01/06/2023 12:19:46 PM
- Mersana Therapeutics Provides Business Update and Announces Strategic Objectives and Expected Milestones • GlobeNewswire Inc. • 01/06/2023 12:00:18 PM
- Current Report Filing (8-k) • Edgar (US Regulatory) • 12/27/2022 12:03:21 PM
- Current Report Filing (8-k) • Edgar (US Regulatory) • 12/22/2022 09:23:22 PM
- Mersana Therapeutics Announces Research Collaboration and Commercial License Agreement with Merck KGaA, Darmstadt, Germany to Develop Novel Immunosynthen Antibody-Drug Conjugates • GlobeNewswire Inc. • 12/22/2022 09:05:10 PM
- Statement of Changes in Beneficial Ownership (4) • Edgar (US Regulatory) • 12/16/2022 09:47:13 PM
- European Commission Designates UpRi as an Orphan Medicinal Product for the Treatment of Ovarian Cancer • GlobeNewswire Inc. • 12/14/2022 01:00:00 PM
- Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 12/02/2022 09:05:00 PM
- Statement of Changes in Beneficial Ownership (4) • Edgar (US Regulatory) • 12/02/2022 09:03:03 PM
- SVB Securities Sticks to Their Buy Rating for Mersana Therapeutics (MRSN) • TipRanks • 11/10/2022 04:27:37 AM
- Robert W. Baird Remains a Buy on Mersana Therapeutics (MRSN) • TipRanks • 11/10/2022 04:16:29 AM
- Mersana Therapeutics to Present at Jefferies London Healthcare Conference • GlobeNewswire Inc. • 11/08/2022 01:00:00 PM
- Current Report Filing (8-k) • Edgar (US Regulatory) • 11/07/2022 09:06:49 PM
- Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) • Edgar (US Regulatory) • 11/07/2022 09:03:59 PM
- Quarterly Report (10-q) • Edgar (US Regulatory) • 11/07/2022 01:49:36 PM
- Current Report Filing (8-k) • Edgar (US Regulatory) • 11/07/2022 12:11:32 PM
- Mersana Therapeutics Provides Business Update and Announces Third Quarter 2022 Financial Results • GlobeNewswire Inc. • 11/07/2022 12:00:00 PM
- Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 11/04/2022 08:05:00 PM
- SVB Securities Keeps Their Buy Rating on Mersana Therapeutics (MRSN) • TipRanks • 11/02/2022 04:45:44 AM
- Mersana Therapeutics to Host Third Quarter 2022 Conference Call on November 7, 2022 • GlobeNewswire Inc. • 10/31/2022 12:00:00 PM
- Analysts Offer Insights on Healthcare Companies: Mersana Therapeutics (MRSN) and Allogene Therapeutics (ALLO) • TipRanks • 10/12/2022 04:30:42 AM
1606 Corp Now Trading under Ticker CBDW, Management Announces First Acquisition • CBDW • Jan 27, 2023 11:59 AM
IQST - iQSTEL Reminds Shareholders To Get Their Votes In Before Annual Meeting Next Week On January 31, 2023 • IQST • Jan 26, 2023 9:53 AM
Nextech AR's AI-Powered CAD to Poly Toggle3D Launches Major Technology Advancements • ARWYF • Jan 26, 2023 8:46 AM
UCASU jump-starts its plan of NASDAQ or NYSE up-listing in 2023 • UCASU • Jan 26, 2023 7:21 AM
Kaya Holdings, Inc. (OTCQB: KAYS) Launches Fifth Dimension Therapeutics™ to seek to Provide Innovative Psychedelic-Based Treatments for Depression and Anxiety Related Conditions and Address the Growing Multi-Billion Dollar Global Psychedelics Market • KAYS • Jan 25, 2023 10:53 AM
B2 Digital's B2 SPORTS NETWORK (B2SN) Expands Distribution to Europe, Russia, and Asia with StayLIVE Agreement • BTDG • Jan 25, 2023 10:00 AM